Persistense with antihypertensives related to formulation: The case of nifedipine

Annals of Pharmacotherapy

Volumn 39, Issue 2, 2005, Pages 237-242

  Breekveldt Postma, Nancy S ^a   Herings, Ron M C ^a  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

Nifedipine; Persistence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COMORBIDITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG USE; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NETHERLANDS; NEWBORN; PRESCRIPTION; PRIORITY JOURNAL; CHEMISTRY; COMPARATIVE STUDY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE; RETROSPECTIVE STUDIES;

EID: 12844266035     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E163     Document Type: Article

References (27)

1. Urquhart J. Internal medicine in the 21st century: controlled drug delivery. Therapeutic and pharmacological aspects. J Intern Med 2000;248:357-76.
2. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001;3:488-92.
3. Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 1994;5:482-504.
4. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
5. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-16.
6. Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987;41:26-30.
7. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet 1996;30:28-51.
8. Procardia nifedipine capsules for oral use. In: Physicians' desk reference. 54th ed. Montvale, NJ: Medical Economics, 2000:2361-3.
9. Mohiuddin SM, Hilleman DE. Substituting nifedipine-GITS for immediate-release calcium-channel antagonists in patients with stable angina pectoris. Curr Ther Res 1991;50:546-52.
10. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
11. Commissie Farmaceutische HuIp CVZ. Farmacotherapeutisch Kompas. Utrecht, 2003.
12. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-26.
13. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
14. Degli Esposti E, Di Martino M, Sturani A, Russo P, Dradi C, Falcinelli S, et al. Risk factors for uncontrolled hypertension in Italy. J Hum Hypertens 2004;18:207-13.
15. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81.
16. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10(7 pt 1):697-704.
17. Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000;76:157-63.
18. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004;164:722-32.
19. Toal CB, Laplante L. Is there a difference in hypertensive patient compliance between a once a day or twice a day nifedipine (abstract)? Am J Hypertension 1995;8(4(2)):D17.
20. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000;35(suppl 3):S23-6.
21. Botero R, Aroca G, Asa G, Gonzalez M. Efficacy and safety of two different formulations of nifedipine (GITS) vs. slow release microgranules in patients with mild and moderate hypertension. J Hum Hypertens 2002;16(suppl 1):S156-60.
22. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Managed Care Pharm 2003;9:424-9.
23. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002;16:439-44.
24. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-56.
25. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7.
26. NIH Publication 98-4080. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD. Arch Intern Med 1997;157:2413-56.
27. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35.